USE OF GNRH IN THE TREATMENT OF PROSTATIC CARCINOMA

GNRH 在治疗前列腺癌中的应用

• 批准号: 3905880
• 负责人: RONALD S SWERDLOFF
• 金额: --
• 依托单位: LOS ANGELES COUNTY HARBOR-UCLA MED CTR
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3905880
• 关键词: drug tolerance; endocrinology; gonadotropin releasing factor; hormone inhibitor; human subject; human therapy evaluation; neoplasm /cancer remission /regression; nutrition; nutrition related tag; pharmacology; prostate neoplasms

To assess the safety, clinical efficacy and tolerance of the daily administration of Buserelin (HOE 766) for at least 12 months in treatment of patients with prostatic carcinoma. Assessment will be made sequentially at 3 month intervals including objective signs of remission, endocrine, nutritional and other biochemical evaluations and patient's quality of life.

评估日常用药的安全性、临床疗效和耐受性 布舍瑞林 (HOE 766) 给药至少 12 个月 前列腺癌患者的治疗。 评估会 每隔 3 个月依次进行，包括客观迹象 缓解、内分泌、营养和其他生化指标 评估和患者的生活质量。